SVR12 rates in mono-infected and co-infected patients treated for 12 weeks without ribavirin were 98 % ( 95 % CI 88-100 ; 43/44 ) and 87 % ( 95 % CI 69-96 ; 26/30 ) , respectively , and with ribavirin were 93 % ( 95 % CI 85-97 ; 79/85 ) and 97 % ( 95 % CI 82-100 ; 28/29 ) , respectively .